Eris Pharmaceuticals (Australia) Pty Ltd

Eris Pharmaceuticals (Australia) Pty Ltd company information, Employees & Contact Information

Eris Pharmaceuticals is an Australian pharmaceutical company whose focus is to bring a range of Australian TGA approved products to global markets. Eris Pharmaceuticals is fast becoming a recognized and accepted brand, showing dynamic growth throughout Australia, the MENA region, CIS Countries and the Balkans. This success has provided a strong foundation for the company to expand its offering and encompass the development, commercialization and marketing of high quality healthcare products. With a hand-picked team of experienced pharmaceutical executives at the coalface, Eris Pharmaceuticals is committed to expanding its coverage in the markets of the Middle East and East Asia. Eris Pharmaceuticals will not only strive to provide the highest quality pharmaceutical products but to help ensure the health and well-being of its patients remains its highest priority.

Company Details

Employees
38
Founded
-
Address
5/148-152 Spit Rd, Mosman,nsw 2088,australia
Email
in****@****rma.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Mosman, NSW
Looking for a particular Eris Pharmaceuticals (Australia) Pty Ltd employee's phone or email?

Eris Pharmaceuticals (Australia) Pty Ltd Questions

News

Eris Lifesciences' unit gets Brazil health regulator nod - The Economic Times

Eris Lifesciences' unit gets Brazil health regulator nod The Economic Times

Eris Lifesciences receives ANVISA approval at its Ahmedabad campus - Indian Pharma Post

Eris Lifesciences receives ANVISA approval at its Ahmedabad campus Indian Pharma Post

Eris Lifesciences post ₹773 cr revenue in Q1 FY26; targets first mover spot in GLP-1 generic - ET Pharma

Eris Lifesciences post ₹773 cr revenue in Q1 FY26; targets first mover spot in GLP-1 generic ET Pharma

Eris Lifesciences' Ahmedabad-based unit gets regulatory approval from Brazil's ANVISA - Business Standard

Eris Lifesciences' Ahmedabad-based unit gets regulatory approval from Brazil's ANVISA Business Standard

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 26% - simplywall.st

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 26% simplywall.st

Eris Lifesciences to launch products in Brazil following facility approval - BioSpectrum India

Eris Lifesciences to launch products in Brazil following facility approval BioSpectrum India

Eris Lifesciences secures ANVISA approval for Ahmedabad manufacturing unit - Express Pharma

Eris Lifesciences secures ANVISA approval for Ahmedabad manufacturing unit Express Pharma

Eris Lifesciences Gets ANVISA Approval for Ahmedabad Unit - India Infoline

Eris Lifesciences Gets ANVISA Approval for Ahmedabad Unit India Infoline

Stocks To Buy: Gillette India, Eris Lifesciences, Tata Motors, Power Grid Corp, Makind Pharma - NDTV Profit

Stocks To Buy: Gillette India, Eris Lifesciences, Tata Motors, Power Grid Corp, Makind Pharma NDTV Profit

Eris Lifesciences Slapped Rs 17 Crore GST Notice Over Novartis Zomelis Deal - Medical Dialogues

Eris Lifesciences Slapped Rs 17 Crore GST Notice Over Novartis Zomelis Deal Medical Dialogues

Biocon continues to divest with $150M sale of insulin and other brands to Eris - Fierce Pharma

Biocon continues to divest with $150M sale of insulin and other brands to Eris Fierce Pharma

Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COO - The Economic Times

Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COO The Economic Times

Eris Lifesciences appoints Murari Ranganathan to drive cardiometabolic business - Indian Pharma Post

Eris Lifesciences appoints Murari Ranganathan to drive cardiometabolic business Indian Pharma Post

Eris Lifesciences Ahmedabad plant receives approval from Brazilian regulator - ET Pharma

Eris Lifesciences Ahmedabad plant receives approval from Brazilian regulator ET Pharma

Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26 - Business Standard

Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26 Business Standard

Mr Ganesh Boddu, GM- Regulatory Affairs & Clinical Research, Eris LifeSciences - Express Pharma

Mr Ganesh Boddu, GM- Regulatory Affairs & Clinical Research, Eris LifeSciences Express Pharma

In debt again, Glenmark seeks buyer for its stake in API business: report - Fierce Pharma

In debt again, Glenmark seeks buyer for its stake in API business: report Fierce Pharma

Eris Lifesciences rises 4% on posting Q4 results; Check all details here - Business Standard

Eris Lifesciences rises 4% on posting Q4 results; Check all details here Business Standard

Eris Lifesciences transfers 100% stake in 2 arms to Eris Therapeutics for Rs 861.9 crore - Medical Dialogues

Eris Lifesciences transfers 100% stake in 2 arms to Eris Therapeutics for Rs 861.9 crore Medical Dialogues

As Novo Nordisk scales back, Eris and Biocon Biologics hit the sweet spot in India’s insulin market - The Economic Times

As Novo Nordisk scales back, Eris and Biocon Biologics hit the sweet spot in India’s insulin market The Economic Times

Eris Lifesciences appoints Murari Ranganathan as president, cardiometabolic business - Pharmabiz.com

Eris Lifesciences appoints Murari Ranganathan as president, cardiometabolic business Pharmabiz.com

Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr - Indian Pharma Post

Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr Indian Pharma Post

Eris Lifesciences acquires Biocon Biologics domestic branded formulation business for Rs 1,242 crore - The Economic Times

Eris Lifesciences acquires Biocon Biologics domestic branded formulation business for Rs 1,242 crore The Economic Times

As COVID-19 vaccine makers gear up to launch updated shots in the private market, can the new vaccines keep up with the virus? - Fierce Pharma

As COVID-19 vaccine makers gear up to launch updated shots in the private market, can the new vaccines keep up with the virus? Fierce Pharma

Eris Lifesciences Acquires Nine Derma Brands From Dr Reddy's Labs For Rs 275 Crores - BW Healthcare World

Eris Lifesciences Acquires Nine Derma Brands From Dr Reddy's Labs For Rs 275 Crores BW Healthcare World

Eris Lifesciences betting on insulin expertise to boost its GLP-1 play | Company Business News - Mint

Eris Lifesciences betting on insulin expertise to boost its GLP-1 play | Company Business News Mint

Eris Lifesciences Q4 net profit Rises 28% to Rs102 crore, Eyes Penfill insulin market - ET Pharma

Eris Lifesciences Q4 net profit Rises 28% to Rs102 crore, Eyes Penfill insulin market ET Pharma

Biocon Biologics, Eris Lifesciences announce long-term collaboration to expand patient access to metabolics, oncology, critical care products - ET HealthWorld

Biocon Biologics, Eris Lifesciences announce long-term collaboration to expand patient access to metabolics, oncology, critical care products ET HealthWorld

Eris Lifesciences Q2FY25 results: Profit skids 25.8%, revenue up 46.6% - Business Standard

Eris Lifesciences Q2FY25 results: Profit skids 25.8%, revenue up 46.6% Business Standard

Eris Lifesciences: Why mutual funds are hiking stake continuously? - Moneycontrol

Eris Lifesciences: Why mutual funds are hiking stake continuously? Moneycontrol

Eris Lifesciences’ profit rises 41 percent on year to Rs 125 crore, driven by domestic branded... - Moneycontrol

Eris Lifesciences’ profit rises 41 percent on year to Rs 125 crore, driven by domestic branded... Moneycontrol

Is Eris Lifesciences Limited (NSE:ERIS) Worth ₹1.8k Based On Its Intrinsic Value? - simplywall.st

Is Eris Lifesciences Limited (NSE:ERIS) Worth ₹1.8k Based On Its Intrinsic Value? simplywall.st

Eris soars 11% on Thursday, zooms 61% from low; is it time to book profit? - Business Standard

Eris soars 11% on Thursday, zooms 61% from low; is it time to book profit? Business Standard

Eris Lifesciences appoints Gopal Agrawal and Nita Borkar to leadership roles - Express Pharma

Eris Lifesciences appoints Gopal Agrawal and Nita Borkar to leadership roles Express Pharma

Eris Lifesciences acquires India-branded formulation business of Biocon Biologics for ₹1,242 crore - BusinessLine

Eris Lifesciences acquires India-branded formulation business of Biocon Biologics for ₹1,242 crore BusinessLine

Briefs: Concord Biotech, Cian Healthcare and Eris Lifesciences - Indian Pharma Post

Briefs: Concord Biotech, Cian Healthcare and Eris Lifesciences Indian Pharma Post

Eris Lifesciences to buy 9 dermatology brands from Glenmark Pharma - Mint

Eris Lifesciences to buy 9 dermatology brands from Glenmark Pharma Mint

Eris Lifesciences to buy some dermatology brands from Glenmark Pharma - The Economic Times

Eris Lifesciences to buy some dermatology brands from Glenmark Pharma The Economic Times

Eris Lifesciences enters Rs 30,000 cr injectables market with Biocon Biologics acquisition - Business Today

Eris Lifesciences enters Rs 30,000 cr injectables market with Biocon Biologics acquisition Business Today

Eris Lifesciences receives ANVISA approval at its Ahmedabad campus - Medical Dialogues

Eris Lifesciences receives ANVISA approval at its Ahmedabad campus Medical Dialogues

Eris Lifesciences acquires 51% in Swiss Parenterals for Rs 637 crore - Moneycontrol

Eris Lifesciences acquires 51% in Swiss Parenterals for Rs 637 crore Moneycontrol

Eris Lifesciences reports 41% year-on-year rise in net profit in Q1 - The Economic Times

Eris Lifesciences reports 41% year-on-year rise in net profit in Q1 The Economic Times

Eris Lifesciences designates Gopal Agrawal, Nita Borkar in leadership roles - Medical Dialogues

Eris Lifesciences designates Gopal Agrawal, Nita Borkar in leadership roles Medical Dialogues

Eris Lifesciences Q4 profit rises 31%, EBITDA margin expands to 36% - CNBC TV18

Eris Lifesciences Q4 profit rises 31%, EBITDA margin expands to 36% CNBC TV18

Eris Lifesciences Secures CDSCO Panel Nod to Conduct BE Study on Dapagliflozin, Pioglitazone, Metformin... - Medical Dialogues

Eris Lifesciences Secures CDSCO Panel Nod to Conduct BE Study on Dapagliflozin, Pioglitazone, Metformin... Medical Dialogues

ERIS Lifesciences Ltd Share Price Today, ERIS Share Price NSE, BSE - Business Today

ERIS Lifesciences Ltd Share Price Today, ERIS Share Price NSE, BSE Business Today

Eris Lifesciences gets ₹17-crore GST show cause notice over Novartis trademark deal - CNBC TV18

Eris Lifesciences gets ₹17-crore GST show cause notice over Novartis trademark deal CNBC TV18

ChrysCapital exits Eris Lifesciences; sells 7.27% stake for Rs 1,187 cr - Business Standard

ChrysCapital exits Eris Lifesciences; sells 7.27% stake for Rs 1,187 cr Business Standard

Eris Lifesciences acquires Oaknet Healthcare for Rs 650 crore - Indian Pharma Post

Eris Lifesciences acquires Oaknet Healthcare for Rs 650 crore Indian Pharma Post

Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly - simplywall.st

Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly simplywall.st

Eris Lifesciences acquires 51 percent stake in Swiss Parenterals to expand its footprint in sterile injectables - financialexpress.com

Eris Lifesciences acquires 51 percent stake in Swiss Parenterals to expand its footprint in sterile injectables financialexpress.com

Eris Lifesciences Q3FY25 results: Profit skids 18.6%, revenue up 49.6% - Business Standard

Eris Lifesciences Q3FY25 results: Profit skids 18.6%, revenue up 49.6% Business Standard

Eris Lifesciences shares drop 5% after profit slides in Q3 results; details - Business Standard

Eris Lifesciences shares drop 5% after profit slides in Q3 results; details Business Standard

Eris Lifesciences Announces Entry into India’s Insulin Market - ET HealthWorld

Eris Lifesciences Announces Entry into India’s Insulin Market ET HealthWorld

Eris Lifesciences to buy Samara-backed Oaknet Healthcare - VCCircle

Eris Lifesciences to buy Samara-backed Oaknet Healthcare VCCircle

Eris Lifesciences signs agreement to buy 51% in Swiss Parenterals for ₹637 crore - BusinessLine

Eris Lifesciences signs agreement to buy 51% in Swiss Parenterals for ₹637 crore BusinessLine

Eris Lifesciences Secures ANVISA Approval for Brazil Entry - Construction World India

Eris Lifesciences Secures ANVISA Approval for Brazil Entry Construction World India

Eris Lifesciences Q3 results: Profit flat at Rs 102 crore, revenue up 16% - Business Standard

Eris Lifesciences Q3 results: Profit flat at Rs 102 crore, revenue up 16% Business Standard

Eris Lifesciences appoints Murari Ranganathan to spearhead Cardiometabolic Business - MarcaMoney

Eris Lifesciences appoints Murari Ranganathan to spearhead Cardiometabolic Business MarcaMoney

Eris Lifesciences acquires nutraceuticals maker UTH Healthcare - VCCircle

Eris Lifesciences acquires nutraceuticals maker UTH Healthcare VCCircle

Eris Lifesciences collaborates with Medtronic - Express Pharma

Eris Lifesciences collaborates with Medtronic Express Pharma

Eris Lifesciences IPO Opens: Should You Invest? - NDTV

Eris Lifesciences IPO Opens: Should You Invest? NDTV

Buy Eris Lifesciences, target price Rs 1100: Prabhudas Lilladher - The Economic Times

Buy Eris Lifesciences, target price Rs 1100: Prabhudas Lilladher The Economic Times

Eris Lifesciences planning new manufacturing facility - Indian Chemical News

Eris Lifesciences planning new manufacturing facility Indian Chemical News

V Krishnakumar joins Eris Lifesciences as Executive Director and COO - Express Pharma

V Krishnakumar joins Eris Lifesciences as Executive Director and COO Express Pharma

Eris Lifesciences, Medtronic develop Guardian Connect to monitor diabetes - Express Healthcare

Eris Lifesciences, Medtronic develop Guardian Connect to monitor diabetes Express Healthcare

ChrysCapital-backed Eris Lifesciences gets SEBI nod for IPO - VCCircle

ChrysCapital-backed Eris Lifesciences gets SEBI nod for IPO VCCircle

Stocks to Watch Today: TCS, Quess Corp, Power Grid Corporation, Eris Lifesciences, Omaxe, Kalpataru... - Moneycontrol

Stocks to Watch Today: TCS, Quess Corp, Power Grid Corporation, Eris Lifesciences, Omaxe, Kalpataru... Moneycontrol

Eris Lifesciences gets Sebi nod for Rs2,000 crore IPO - Mint

Eris Lifesciences gets Sebi nod for Rs2,000 crore IPO Mint

Eris Lifesciences and PlexusMD come up with 'Saarthi' - Express Healthcare

Eris Lifesciences and PlexusMD come up with 'Saarthi' Express Healthcare

Eris Life Sciences: Drug Money - Forbes India

Eris Life Sciences: Drug Money Forbes India

Emerging companies of India: Eris Lifesciences - Business Today

Emerging companies of India: Eris Lifesciences Business Today

Eris Lifesciences: Costly prescription - Business Standard

Eris Lifesciences: Costly prescription Business Standard

Stock Alert: Eris Lifesciences, Power Grid Corp, Bharat Electronics, Acme Solar Holdings, Ashok Leyland - Business Standard

Stock Alert: Eris Lifesciences, Power Grid Corp, Bharat Electronics, Acme Solar Holdings, Ashok Leyland Business Standard

Eris Lifesciences hits record low as stock turns ex-date for share buyback - Business Standard

Eris Lifesciences hits record low as stock turns ex-date for share buyback Business Standard

Eris Lifesciences hits an all-time high on the back of strong Q2 results; here's what Anil Singhvi says about it - Zee Business

Eris Lifesciences hits an all-time high on the back of strong Q2 results; here's what Anil Singhvi says about it Zee Business

Top Eris Pharmaceuticals (Australia) Pty Ltd Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant